Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18305611 | 0.86 | ALDH1A1 (0.35) | TRPV4KDM4EALDH1A1PGRMEN1 | |
| SCHEMBL25322172 | 0.79 | ALDH1A1 (0.32) | TRPV4KDM4EALDH1A1GAAHPGD | |
| SCHEMBL25318072 | 0.75 | ALDH1A1 (0.37) | KDM4EALDH1A1MEN1GAAKMT2A | |
| SCHEMBL25044664 | 0.71 | TRPV4 (0.35) | TRPV4 | |
| SCHEMBL30507851 | 0.71 | TRPV4 (0.35) | TRPV4 | |
| SCHEMBL8948524 | 0.71 | ALDH1A1 (0.36) | KDM4EALDH1A1PGRMEN1GAA | |
| SCHEMBL25318760 | 0.71 | MAOA (0.33) | TRPV4KDM4EMAPTPOLB | |
| SCHEMBL25430712 | 0.70 | IRAK4 (0.31) | — | |
| SCHEMBL18305749 | 0.69 | PDE4A (0.35) | TRPV4KDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL35767595 | 0.69 | PDE4A (0.35) | TRPV4KDM4EALDH1A1GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059204-A1 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-02-20 | — | — | US | disclosed |
| EP-4448109-A1 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | Aurigene Oncology Limited (IN) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023114710-A1 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114710-A1 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059204-A1 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | TRPV4 4085/4885KDM4E 506/4885ALDH1A1 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.